2022年AACR会议于当地时间04月08日-04月13日在美国路易斯安那州新奥尔良盛大开幕，今年会议的主题是“Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes
”。会议火热进行，各项重磅研究相继公布。本期内容【肿瘤资讯】为您整理了血液肿瘤研究汇总——骨髓瘤&淋巴瘤篇！后续小编将持续跟进相关内容！
骨髓瘤
临床试验
1. 新型IKZF1/3降解物CFT7455用于MM的首次人体(FIH)i/ii期研究的初始治疗队列的结果大公开
题目：Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
时间：April 12, 2022, 9:00 AM - 12:30 PM
会议类型：Session PO.CT01.02 - Phase I Clinical Trials 2
演讲者：Sagar Lonial,
摘要号：CT186 / 11
New Drugs
1. CFT7455的发现和表征：IKZF1/3的强效选择性降解剂，用于治疗复发性/难治性多发性骨髓瘤
题目：The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma
时间：April 11, 2022, 11:00 AM - 11:15 AM
会议类型：Session DDT003 - New Drugs on the Horizon: Part 3
演讲者：James A. Henderson
摘要号：ND13
淋巴瘤
临床试验
1.固有细胞衔接系统(ICE®)AFM13联合预活化和扩增的脐带血(CB)源性NK细胞治疗难治性/复发性CD30 + 淋巴瘤患者
题目：Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma
时间：April 10, 2022, 2:01 PM - 2:16 PM
会议类型：Session CTPL01 - Clinical Trials of Cellular Immunotherapies
演讲者：Yago Nieto
摘要号：CT003
2. axicabtagene ciloleucel(axi-cel)二线治疗大B细胞淋巴瘤的疗效和毒性
题目：Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma
时间：April 10, 2022, 2:31 PM - 2:46 PM
会议类型：Session CTPL01 - Clinical Trials of Cellular Immunotherapies
演讲者：Jason R. Westin
摘要号：CT004
3. IGM-2323治疗复发/难治性非霍奇金淋巴瘤的i/ii期随机研究
题目：A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas
时间：April 11, 2022, 9:00 AM - 12:30 PM
会议类型：Session PO.CT02.03 - Phase II Trials in Progress
演讲者：Loretta Nastoupil,
摘要号：CT125 / 7
4. 一项 正在进行，开放标签、多中心 CAPITAL II期试验：强效口服泛AKT抑制剂capivaserti治疗复发性或难治性B细胞非霍奇金淋巴瘤患者
题目：Trial in progress: A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor in patients with relapsed or refractory B-cell non-hodgkin lymphoma (CAPITAL)
时间：April 11, 2022, 9:00 AM - 12:30 PM
会议类型：Session PO.CT02.03 - Phase II Trials in Progress
演讲者：Michael Wang
摘要号：CT127 / 10
5. CD4-CAR-T治疗复发性或难治性T细胞淋巴瘤(TCL)的1期、开放性、多中心、多队列研究
题目：A phase 1, open-label, multicenter, multicohort study of CD4-targeted chimeric antigen receptor T cells (CD4-CAR-T) in relapsed or refractory T-cell lymphoma (TCL)
时间：April 12, 2022, 9:00 AM - 12:30 PM
会议类型：
Session PO.CT01.03 - Phase I Trials in Progress 1
演讲者：Swaminathan P.
摘要号：CT215 / 15
LBA
1. 在一项copanlisib联合利妥昔单抗治疗惰性非霍奇金淋巴瘤(iNHL)患者的III期研究中PTEN蛋白表达和基因表达谱(GEP)的生物标志物评估
题目：Biomarker assessment of PTEN protein expression and gene expression profiling (GEP) in a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL)
时间：April 8, 2022, 12:00 PM - 1:00 PM
会议类型：Session OPO.ET06.01 - Small Molecule Therapeutic Agents
演讲者：Shalini Chaturvedi
摘要号：LB523
2 解旋酶DDX3X的X连锁基因是淋巴分化和MYC驱动的淋巴瘤发生所必需的条件
题目：The X-linked gene for the helicase DDX3X is required for lymphoid differentiation and MYC-driven lymphomagenesis
时间：April 8, 2022, 12:00 PM - 1:00 PM
会议类型：Session OPO.MCB01.01 - Cell Growth Signaling Pathways
演讲者：Marion Lacroix
摘要号：LB559
1.Sagar Lonial, Shambavi Richard, Jeffrey V Matous, et al. Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM. 2022 AACR abs CT186 / 11.
2. James A. Henderson, Scott J. Eron, Andrew Good, et al. The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma. 2022 AACR abs ND13.
3. Yago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. 2022 AACR abs CT003.
4. Simone Filosto, Saran Vardhanabhuti, Miguel Canales, et al. Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma. 2022 AACR abs CT004.
5. Loretta Nastoupil, Elizabeth Budde, Won Seog Kim, et al. Pr A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas. 2022 AACR abs CT125 / 7.
6. Michael Wang, Ho-Jin Shin, Alex F. Herrera, et al. Trial in progress: A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor in patients with relapsed or refractory B-cell non-hodgkin lymphoma (CAPITAL). 2022 AACR abs CT127 / 10.
7. Swaminathan P. Lyer, David G. Maloney, Nora Bennani, et al. LB1901: A phase 1, open-label, multicenter, multicohort study of CD4-targeted chimeric antigen receptor T cells (CD4-CAR-T) in relapsed or refractory T-cell lymphoma (TCL). 2022 AACR abs CT215 / 15.
8. Shalini Chaturvedi, Anke Schulz, Lidia Mongay Soler, et al. LB1901: Biomarker assessment of PTEN protein expression and gene expression profiling (GEP) in a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL). 2022 AACR abs LB523.
9. Marion Lacroix, Hugues Beauchemin, Julie Ross, et al. LB1901: The X-linked gene for the helicase DDX3X is required for lymphoid differentiation and MYC-driven lymphomagenesis. 2022 AACR abs LB559
排版编辑：肿瘤资讯-luna
苏公网安备32059002004080号
